Company news
Shield Therapeutics Plc (LSE:STX) news
Shield Therapeutics Plc news releases on 6ix. Latest, May 11, 2020: Shield Therapeutics (STX): Reassuring trading u...
Press releases — page 4
Shield Therapeutics (STX): Reassuring trading u...
May 11, 2020
Further re. Directorate Change
April 27, 2020
AEGIS-H2H study update
March 17, 2020
Shield Therapeutics (STX): Good demand for Fera...
January 28, 2020
Shield Therapeutics (STX): Taking on China
January 14, 2020
China licence agreement for Feraccru/Accrufer
January 8, 2020
QCA Corporate Governance Code
November 25, 2019
Shield Therapeutics (STX): More choice for clin...
October 30, 2019
Positive results presented at UEG Week 2019
October 22, 2019
Shield Therapeutics (STX): FDA approval ushers ...
September 2, 2019
Shield Therapeutics (STX) FDA approval opens do...
August 5, 2019
FDA approves Feraccru® with a broad label
July 26, 2019
Additional Listing
July 2, 2019
Update on Legal Proceedings
June 3, 2019
Shield Therapeutics (STX): All in the execution
May 13, 2019
Appointment of Joint Broker
May 8, 2019
2018 Annual Report and 2019 AGM Notice
April 30, 2019
PDMR Acquisition of Shares
April 26, 2019
Major extension to approval in Switzerland
April 24, 2019
PDMR Acquisition of Shares and Additional Listing
April 17, 2019
Final Results
April 3, 2019
Change of Adviser
April 1, 2019
Positive decision on Feraccru®'s process patent
March 14, 2019
Positive results for Feraccru® in AEGIS-H2H study
March 4, 2019
Positive results of AEGIS-CKD study
January 29, 2019
Shield Therapeutics (STX): Cast-iron investment
January 28, 2019
US New Drug Application PDUFA date for Feraccru
December 13, 2018
UK launch of Feraccru® by Norgine
December 5, 2018
New Drug Application for Feraccru®
December 3, 2018
Notification Of Major Holdings
October 1, 2018
Licence for the commercialisation of Feraccru
September 19, 2018
AEGIS-H2H Completion of Recruitment
September 13, 2018
Business Update
July 23, 2018
Holdings in Company
July 9, 2018
Data from real-world clinical use of Feraccru
June 28, 2018
Positive top-line results from AEGIS-PAED PK study
June 14, 2018
2017 Annual Report and 2018 AGM Notice
June 5, 2018
Preliminary Results for the Year Ended 31 Dec 17
April 11, 2018
Results of Pre-Submission Meeting with FDA
April 6, 2018
Broadening of Feraccru indication
March 27, 2018
Update on the AEGIS-CKD study
March 16, 2018
Receives CHMP positive opinion on Feraccru®
February 23, 2018
Business and Trading Update
February 22, 2018
Top-line results from Feraccru Phase III study
February 5, 2018
Completion of patient enrolment in Phase 3 study
October 10, 2017
Interim Report
September 20, 2017
Board Change
September 14, 2017
US Composition of Matter Patent Allowed
September 6, 2017
Shield to Present at Baird Healthcare Conference
August 31, 2017
Grant of Share Options
July 11, 2017